Michael C. Wimer

Array ( [id] => 19297509 [patent_doc_number] => 20240226074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => CELL-OF-ORIGIN TARGETED DRUG REPURPOSING FOR TRIPLE-NEGATIVE AND INFLAMMATORY BREAST CARCINOMA WITH HDAC AND HSP90 INHIBITORS COMBINED WITH NICLOSAMIDE [patent_app_type] => utility [patent_app_number] => 18/540647 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19249159 [patent_doc_number] => 20240200146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 18/516552 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19996628 [patent_doc_number] => 20250134850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => PLANT-DERIVED SMALL MOLECULES AS MARBURG VIRUS INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/499733 [patent_app_country] => US [patent_app_date] => 2023-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6153 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18499733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987750 [patent_doc_number] => 20240059719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => GOLD COMPLEXES AS ANTICANCER AGENT [patent_app_type] => utility [patent_app_number] => 18/383517 [patent_app_country] => US [patent_app_date] => 2023-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953490 [patent_doc_number] => 20240041817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION [patent_app_type] => utility [patent_app_number] => 18/486623 [patent_app_country] => US [patent_app_date] => 2023-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18486623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19279874 [patent_doc_number] => 20240216346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same [patent_app_type] => utility [patent_app_number] => 18/376983 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18376983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860064 [patent_doc_number] => 20230414498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => METHODS OF TREATING EOSINOPHILIC ESOPHAGITIS [patent_app_type] => utility [patent_app_number] => 18/244500 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18244500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19155998 [patent_doc_number] => 20240148704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS) [patent_app_type] => utility [patent_app_number] => 18/241355 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034044 [patent_doc_number] => 20240083859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => Bi-functional Molecules To Degrade Circulating Proteins [patent_app_type] => utility [patent_app_number] => 18/446296 [patent_app_country] => US [patent_app_date] => 2023-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18446296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19001900 [patent_doc_number] => 20240065971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE [patent_app_type] => utility [patent_app_number] => 17/881302 [patent_app_country] => US [patent_app_date] => 2023-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17881302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786023 [patent_doc_number] => 20230373954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => NOVEL ACID SECRETION INHIBITOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/228672 [patent_app_country] => US [patent_app_date] => 2023-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18228672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19008738 [patent_doc_number] => 20240072809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS [patent_app_type] => utility [patent_app_number] => 18/220708 [patent_app_country] => US [patent_app_date] => 2023-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88082 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18220708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893679 [patent_doc_number] => 20240009164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => METHODS AND COMPOUNDS FOR TREATING ULCERATIVE COLITIS [patent_app_type] => utility [patent_app_number] => 18/349452 [patent_app_country] => US [patent_app_date] => 2023-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18349452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466530 [patent_doc_number] => 12522562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Intestine-specific partial agonists of farnesoid X receptor and uses thereof [patent_app_type] => utility [patent_app_number] => 18/213985 [patent_app_country] => US [patent_app_date] => 2023-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 9036 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18213985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19179880 [patent_doc_number] => 11986454 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-21 [patent_title] => Methods of providing solriamfetol therapy to subjects with impaired renal function [patent_app_type] => utility [patent_app_number] => 18/340005 [patent_app_country] => US [patent_app_date] => 2023-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21147 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20742909 [patent_doc_number] => 12642791 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-02 [patent_title] => Inhibitors of lysyl oxidases [patent_app_type] => utility [patent_app_number] => 18/333162 [patent_app_country] => US [patent_app_date] => 2023-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 46 [patent_no_of_words] => 14745 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18333162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18626592 [patent_doc_number] => 20230285384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => USING GENO- OR PHENOTYPING TO ADJUST LSD DOSING [patent_app_type] => utility [patent_app_number] => 18/321159 [patent_app_country] => US [patent_app_date] => 2023-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18321159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217720 [patent_doc_number] => 20240182424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => ENHANCED ERYTHROPOIESIS AND IRON METABOLISM [patent_app_type] => utility [patent_app_number] => 18/317195 [patent_app_country] => US [patent_app_date] => 2023-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18317195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752334 [patent_doc_number] => 20230355561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => N-ACETYLCYSTEINE ATTENUATES AORTIC STENOSIS PROGRESSION BY INHIBITING SHEAR-MEDIATED TGF-BETA ACTIVATION AND FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/197567 [patent_app_country] => US [patent_app_date] => 2023-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18197567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18581512 [patent_doc_number] => 20230263764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION [patent_app_type] => utility [patent_app_number] => 18/295114 [patent_app_country] => US [patent_app_date] => 2023-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18295114 [rel_patent_id] =>[rel_patent_doc_number] =>)